HOME >> BIOLOGY >> NEWS
Phase 3 psoriatic arthritis data for ENBREL (etanercept) announced at a national scientific meeting

is the only tumor necrosis factor (TNF) inhibitor approved for use without methotrexate. It is also the only TNF inhibitor approved for use as a first-line therapy for RA.

ENBREL acts by binding TNF, one of the dominant cytokines or regulatory proteins that play an important role in both normal immune function and the cascade of reactions that cause the inflammatory process of RA and psoriatic arthritis. ENBREL competitively inhibits binding of TNF molecules to the TNF receptor sites. The binding of ENBREL to TNF renders the bound TNF biologically inactive, resulting in significant reduction in inflammatory activity.

SINCE THE PRODUCT WAS FIRST INTRODUCED, SERIOUS INFECTIONS, SOME INVOLVING DEATH, HAVE BEEN REPORTED IN PATIENTS USING ENBREL. MANY OF THESE INFECTIONS OCCURRED IN PATIENTS WHO WERE PRONE TO INFECTIONS, SUCH AS THOSE WITH ADVANCED OR POORLY CONTROLLED DIABETES. RARE CASES OF TUBERCULOSIS HAVE ALSO BEEN REPORTED. ENBREL SHOULD BE DISCONTINUED IN PATIENTS WITH SERIOUS INFECTIONS. DO NOT START ENBREL IF YOU HAVE AN INFECTION OF ANY TYPE OR IF YOU HAVE AN ALLERGY TO ENBREL OR ITS COMPONENTS. ENBREL SHOULD BE USED WITH CAUTION IN PATIENTS PRONE TO INFECTION. CONTACT YOUR PHYSICIAN IF YOU HAVE ANY QUESTIONS ABOUT ENBREL OR INFECTIONS.

There have been rare reports of serious nervous system disorders such as multiple sclerosis, seizures or inflammation of the nerves of the eyes. Tell your doctor if you have ever had any of these disorders or if you develop them after starting ENBREL. There have also been rare reports of serious blood disorders, some involving death. Contact your doctor immediately if you develop symptoms such as persistent fever, bruising, bleeding, or paleness. It is unclear if ENBREL (etanercept) has caused these nervous system or blood disorders. If your doctor confirms serious blood problems, you may need to stop using ENBREL.

The most frequent adverse events in placebo-controlled clinical trials involvin
'"/>


12-Nov-2001


Page: 1 2 3 4 5

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. OneWorld Health completes enrollment, treatment in Phase III India trial
3. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
4. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
5. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
6. KEPPRA international Phase IV SKATE study results show favourable efficacy
7. Phase III study results with Raptiva in the treatment of psoriasis presented at Annual AAD meeting
8. Phase III, 48-Wk NEAT study results comparing GW433908 to Nelfinavir presented today
9. OXiGENE announces commencement of Phase I/II clinical trial of Combretastatin A4 Prodrug
10. Acorda therapeutics receives NIH Phase 2 grant for central nervous system repair
11. Phase transition in bilayers could affect their performance

Post Your Comments:
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:4/2/2015)... April 2, 2015 At its 2015 ACMG ... City , the American College of Medical Genetics ... directors to its Board.  Members of the ACMG Board ... for forming and advancing its policies and programs. ACMG ... "It,s an eventful time in medical genetics ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
(Date:4/20/2015)... , April 20, 2015   Meditope Biosciences, ... using its proprietary technology, today announced presentation of data ... the development of antibody-drug conjugates (ADCs). The data were presented ... taking place April 18-22 in Philadelphia ... these data which point to the many commercial applications ...
(Date:4/20/2015)... 2015 Whitehouse Laboratories is pleased and ... most recent Food and Drug Administration (FDA) inspection and ... five day, GMP compliance inspection, as based upon 21CFR ... through April 6th and was granted NAI (no action ... the strict Good Manufacturing Practice (GMP) quality system required ...
(Date:4/17/2015)... ALTO, Calif. , April 17, 2015 ... has received a SBIR grant from the ... the National Institutes of Health (NIH). The ... research efforts in the development of breakthrough ... genomes using specially fabricated substrates. Centrillion has ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 CIO Review ... for its 20 Most Promising Pharma and Life Science ... MMIS’s MediSpend global compliance software platform for life sciences ... selected by a panel of experts and members of ... entrepreneurship. “MMIS’s MediSpend Platform has been on our radar ...
Breaking Biology Technology:Meditope Biosciences Presents Data At The American Association Of Cancer Research (AACR) Annual Meeting Validating Its SnAP Technology Platform 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 3MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2
Cached News: